|
α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→3)-[β-D-Galp-(1→4)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→6)]-β-D-Man-(1→4)-β-D-GlcpNAc-(1→4)-[α-L-Fucp-(1→6)]-β-D-GlcpNAc |
|
CHEBI:139412 |
|
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc |
|
An amino oligosaccharide that is a branched undecasaccharide derivative consisting of a heptasaccharide chain of α-sialyl, β-D-galactose, N-acetyl-β-D-glucosamine, α-D-mannose, β-D-mannose, and two N-acetyl-β-D-glucosamine residues linked sequentially (2→3), (1→4), (1→2), (1→3), (1→4) and (1→4), to the β-D-mannose residue of which is (1→6)-linked a β-D-galactosyl-(1→4)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-mannosyl tetrasaccharide branch and to the reducing end N-acetyl-β-D-glucosamine residue of which is (1→6)-linked an α-L-fucose residue. When it is the N-glycan content of the tumour necrosis factor (TNF) alpha blocker cetuximab, the terminal Neu5Ac residue may be replaced by Neu5Gc, while the fucose residue may be absent. When it is the N-glycan content of the tumour necrosis factor (TNF) alpha blocker infliximab, the terminal Neu5Ac residue may be replaced by Neu5Gc, while one or both of the fucose and terminal galactose residues may be absent. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
|
Molfile
XML
SDF
|
|
|
|
InChI=1S/C85H141N5O63/c1-19-42(107)53(118)58(123)77(133-19)131-18-36-67(49(114)38(73(128)134-36)87-21(3)101)144-74-39(88-22(4)102)50(115)64(32(14-97)139-74)146-80-61(126)69(48(113)35(143-80)17-132-82-71(55(120)45(110)28(10-93)137-82)150-75-40(89-23(5)103)51(116)63(31(13-96)140-75)145-79-60(125)57(122)66(34(16-99)142-79)148-78-59(124)54(119)44(109)27(9-92)135-78)149-83-72(56(121)46(111)29(11-94)138-83)151-76-41(90-24(6)104)52(117)65(33(15-98)141-76)147-81-62(127)70(47(112)30(12-95)136-81)153-85(84(129)130)7-25(105)37(86-20(2)100)68(152-85)43(108)26(106)8-91/h19,25-83,91-99,105-128H,7-18H2,1-6H3,(H,86,100)(H,87,101)(H,88,102)(H,89,103)(H,90,104)(H,129,130)/t19-,25-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45+,46+,47-,48+,49+,50+,51+,52+,53+,54-,55-,56-,57+,58-,59+,60+,61-,62+,63+,64+,65+,66-,67+,68+,69-,70-,71-,72-,73+,74-,75-,76-,77+,78-,79-,80-,81-,82-,83+,85-/m0/s1 |
BSFVQLGLKDTWKI-QYLKTMJBSA-N |
O[C@H]1[C@@H]([C@@H]([C@H](O[C@@H]1CO)O[C@@H]2[C@@H]([C@@H](O[C@@H]([C@H]2O)CO[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O)O)O)O)O)NC(C)=O)O[C@H]7[C@@H]([C@H]([C@@H](O[C@@H]7CO)O[C@H]8[C@@H]([C@H]([C@@H](O[C@@H]8CO[C@H]9[C@H]([C@@H]([C@@H]([C@@H](O9)C)O)O)O)O)NC(C)=O)O)NC(C)=O)O)O)O[C@H]%10[C@@H]([C@H]([C@@H]([C@H](O%10)CO)O[C@H]%11[C@@H]([C@H]([C@H]([C@H](O%11)CO)O)O[C@]%12(O[C@]([C@@H]([C@H](C%12)O)NC(C)=O)([C@@H]([C@@H](CO)O)O)[H])C(O)=O)O)O)NC(C)=O)O |
|
Outgoing
|
α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→3)-[β-D-Galp-(1→4)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→6)]-β-D-Man-(1→4)-β-D-GlcpNAc-(1→4)-[α-L-Fucp-(1→6)]-β-D-GlcpNAc
(CHEBI:139412)
is a
N-glycan derivative
(CHEBI:71275)
α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→3)-[β-D-Galp-(1→4)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→6)]-β-D-Man-(1→4)-β-D-GlcpNAc-(1→4)-[α-L-Fucp-(1→6)]-β-D-GlcpNAc
(CHEBI:139412)
is a
amino oligosaccharide
(CHEBI:22483)
α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→3)-[β-D-Galp-(1→4)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→2)-α-D-Manp-(1→6)]-β-D-Man-(1→4)-β-D-GlcpNAc-(1→4)-[α-L-Fucp-(1→6)]-β-D-GlcpNAc
(CHEBI:139412)
is a
glucosamine oligosaccharide
(CHEBI:22485)
|
|
5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranonosyl-(2→3)-β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)-[β-D-galactopyranosyl-(1→4)-β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-β-D-mannopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-[α-L-fucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranose
|
α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-β-D-GlcNAc-(1→2)-α-D-Man-(1→3)-[β-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-GlcNAc-(1→2)-α-D-Man-(1→6)]-β-D-Man-(1→4)-β-D-GlcNAc-(1→4)-[α-L-Fuc-(1→6)]-β-D-GlcNAc
|
ChEBI
|
α-sialyl-(2→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl-(1→2)-α-D-mannosyl-(1→3)-[β-D-galactosyl-(1→4)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl-(1→2)-α-D-mannosyl-(1→6)]-β-D-mannosyl-(1→4)-N-acetyl-β-D-glucosaminyl-(1→4)-[α-L-fucosyl-(1→6)]-N-acetyl-β-D-glucosamine
|
ChEBI
|
Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAcβ
|
ChEBI
|
29187897
|
PubMed citation
|
Europe PMC
|
|